Intelligent Bio Solutions Launches FDA Study for U.S. Drug Screening System Clearance
Event summary
- Intelligent Bio Solutions has initiated a multi-site Method Comparison Study to support FDA 510(k) submission for its drug screening system.
- The study, conducted with CenExel Clinical Research, will enroll 135 participants across nine operator sites.
- Data collection is expected to conclude by the end of July 2026.
- The study aims to validate the system's accuracy and ease of use by typical workplace personnel.
The big picture
The study is a critical step for Intelligent Bio Solutions to gain FDA clearance for its non-invasive drug screening system, which could disrupt the workplace drug testing market. The company's focus on real-world performance validation aligns with broader industry trends toward simplified, accurate, and cost-effective diagnostic tools. Success in this study could accelerate its entry into the U.S. market, where workplace drug screening is a multi-billion-dollar industry.
What we're watching
- Regulatory Timing
- Whether the study results will meet FDA requirements for a smooth 510(k) submission process.
- Market Differentiation
- How the system's ease of use will position it against traditional drug screening methods.
- Execution Risk
- The pace at which Intelligent Bio Solutions can scale its U.S. market entry post-approval.